TTR and cardiac amyloidosis: This is consistent with the recent Clinical Consensus Statement from the European Heart Rhythm Association (EHRA), which identifies amyloidogenesis as one of the pathophysiological mechanisms underlying atrial cardiomyopathy—whether in the context of transthyretin (TTR)-related or light-chain (AL)-related amyloid cardiomyopathy, or as an isolated condition, such as isolated atrial amyloidosis (IAA).9